Mirena, a 52-milligram levonorgestrel intrauterine device for contraception, carries a small but real acne risk. Most users keep the device, and skin changes can often be managed without removal.
This guide explains the numbers, the limits, and sensible next steps. Acne appears alongside other hormone-linked reports such as hair shedding and unwanted hair growth. Trial rates, large report databases, and follow-up studies each answer a different part of that picture.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How common is acne with Mirena?
- Why do safety reports sound worse than trials?
- Who notices breakouts most?
- What should you discuss with your clinician?
How common is acne with Mirena?
The U.S. National Library of Medicine DailyMed Mirena label reports acne in 6.8% of clinical-trial users in the DailyMed Mirena label. In the same trials, hair loss, excess hair growth, nausea, expulsion, and pelvic infection each stayed below 5%.
Medical Dialogues, reporting a January 2025 American Journal of Obstetrics and Gynecology study, found low early discontinuation in the early-discontinuation study summary. Only 83 of about 1,500 new 52-milligram users, 5.5%, stopped for hormone-related effects within six months. About 1.0% stopped specifically because of acne.
Why do safety reports sound worse than trials?
Medical Dialogues, reporting Cassard and colleagues in the Journal of the American Academy of Dermatology, analyzed 139,348 levonorgestrel-IUD reports and 50,450 copper-IUD reports in the FAERS dermatology analysis. Levonorgestrel devices showed higher reporting odds for acne, hair loss, and excess hair growth. Mirena 52 mg had an acne-reporting odds ratio of 3.40 versus copper IUDs, near Kyleena 19.5 mg at 3.42.
Reporting odds do not equal true incidence. Medical Dialogues notes the FAERS data lacked prior-medication history and used routine records without standardized dermatologist grading for teens. Those gaps make direct risk comparisons difficult without trial and clinic follow-up data.
Who notices breakouts most?
Healio, reporting Boos and colleagues in Pediatric Dermatology, found new or worsened acne risk with progestin-only long-acting contraception, especially in younger users. Acne alone uncommonly led those adolescents and young adults to remove the device.
Practical Dermatology, summarizing Boos and counseling discussion, points to a switch effect. Stopping combined hormonal contraception removes estrogen that had suppressed acne. Breakouts after a levonorgestrel IUD starts may reflect that loss, not entirely new disease.
What should you discuss with your clinician?
The American College of Obstetricians and Gynecologists advises counseling about acne, hair loss, and excess hair before insertion. That conversation helps set expectations and preserves choice.
Standard acne care remains the usual first response, with removal reserved for personal preference or severe burden. Bring breakout photos, a list of past birth-control methods, and your acne-control priorities to that visit.
- Ask about standard acne treatment first, rather than automatic removal.
- Review prior combined methods and current breakouts with dates and photos.
- Discuss estrogen-progestin options if acne control is a top priority.